Management of bone metastases in prostate cancer
Authors:
- Fred SaadFSFred Saad
- 1 September 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Supportive & Palliative Care
- Vol. 9 (3) , 261-267
Abstract
Bone metastases in the advanced stages of prostate cancer have a detrimental effect on the quality of life, resulting in skeletal-related events and pain and place a significant burden on healthcare resources. Improvements in prostate cancer treatment have led to a longer survival of patients. Therefore, quality of life is of growing interest and importance. Successful management and prevention of the complications of bone metastasis in those patients remains, however, clinically challenging. Recently, radium-223 was approved as a treatment for bone metastasis in patients with prostate cancer, joining zoledronic acid, denosumab and other radiopharmaceuticals in the clinical armamentarium. Radium-223 has shown to improve overall survival in patients with bone metastasis. This review focuses on the recent landmark studies on zoledronic acid, denosumab and radium-223 for patients with metastatic prostate cancer and gives a comprehensive overview of their mechanism of action, efficacy, dosage and safety profile.Keywords
This publication has 27 references indexed in Scilit:
- Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving ParadigmsProstate Cancer, 2013
- How Do I Treat Patients with Bone Metastases?Oncology Times, 2013
- Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- New and Emerging Therapies for Bone Metastases in Genitourinary CancersEuropean Urology, 2013
- Bone-Targeting Radiopharmaceuticals Including Radium-223The Cancer Journal, 2013
- Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone diseaseCancer Management and Research, 2013
- Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practiceCanadian Urological Association Journal, 2012
- Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trialsEuropean Journal of Cancer, 2012
- First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal MetastasesClinical Cancer Research, 2005
- Bisphosphonates: Preclinical ReviewThe Oncologist, 2004